Business context and reporting period
The filing is for Nuvilex, Inc., a preclinical- and clinical-stage biotechnology company developing treatments using its Cell-in-a-Box live-cell encapsulation technology. It reports the quarter and six months ended October 31, 2014, compared with the same periods in 2013; the balance sheet compares October 31, 2014 with April 30, 2014. The company describes preparations for a Phase 2b pancreatic cancer trial in Australia and U.S. studies of pancreatic-cancer symptoms, alongside diabetes-related development.
Identity and period caveat: The request identifies Pharmacyte Biotech, Inc., but the filing names Nuvilex, Inc. The filing’s index also refers to a three-month period ended July 31, 2014, inconsistent with the October 31 period shown on the cover and in the financial statements. Verify the issuer and reporting period before relying on this summary.
Financial results and position
| Metric | Three months ended Oct. 31, 2014 | Six months ended Oct. 31, 2014 | Comparable 2013 period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Operating expenses | $6.25 million | $7.83 million | $0.45 million and $1.85 million, respectively |
| Operating loss | $6.25 million | $7.83 million | $0.45 million and $1.85 million, respectively |
| Net loss | $4.06 million | $5.65 million | $5.66 million and $10.32 million, respectively |
| Loss per share | $0.01 | $0.01 | $0.01 and $0.02, respectively |
- There was no revenue or gross margin in either period. Conventional revenue-based margins are not meaningful.
- Six-month operating cash use was $2.15 million; investing cash use was $250,000, primarily for licenses and patents; financing cash use was $57,859. Cash fell $2.46 million to $1.16 million from $3.62 million at April 30.
- At October 31, current assets were $1.28 million and current liabilities were $276,862. Total liabilities were $276,862, with no long-term debt reported. The company had $6.66 million in assets and $6.38 million in stockholders’ equity.
- Accumulated deficit was $75.61 million. The six-month net loss was lower than in 2013 despite higher operating expenses, in part because 2013 included substantial non-cash losses on preferred-stock conversion and debt settlement. The 2014 quarter also included a $2.18 million non-cash gain from returned shares.
Material changes and notable items
- Six-month compensation expense increased to $5.09 million from $862,261. A principal driver was a $4.31 million non-cash charge for 25 million fully vested options granted to officers and directors, exercisable at $0.19 per share.
- Six-month general and administrative expense rose to $1.54 million from $284,486; legal and professional expense rose to $614,094 from $207,514; and research and development expense was $347,763 versus none in 2013. Management attributed increases to the company’s biotechnology focus, research, legal work, travel, investor relations, and consulting.
- Common shares issued and outstanding increased to 696.1 million at October 31 from 690.6 million at April 30. In addition, 57.97 million warrants were outstanding, and the filing reported 1.7 million shares committed for officer compensation but not yet issued at quarter-end.
- The company completed its Bio Blue Bird acquisition in April 2014, obtaining cancer-related licensing rights and a 14.5% interest in SG Austria. It also holds an exclusive diabetes license; valuations of the SG Austria investment and related contingent payment liability were still underway.
Outlook, risks and contingencies
- Management said October 31 cash was expected to fund operations through October 31, 2015, but also stated that substantial additional capital would be needed and that the company would remain dependent on outside funding. It warned that failure to obtain capital could require delaying or abandoning plans. This runway estimate preceded the subsequent cannabinoid-license payment obligations.
- Management’s stated priorities included preparing the Australian Phase 2b pancreatic cancer trial, conducting U.S. preclinical and clinical work on pancreatic-cancer symptoms, and pursuing development and partnering opportunities. The filing provides no quantified revenue or earnings guidance and no assurance of trial success or regulatory approval.
- A November 24, 2014 agreement with Austrianova, effective December 1, licensed Cell-in-a-Box technology for cannabinoid-related research and commercialization. Terms included a $2 million initial fee due by June 30, 2015, 10% royalties on direct sales and 20% on sublicensee sales, plus milestone payments of $100,000 to $1 million. The filing says $500,000 had been paid, but its disclosures give inconsistent payment timing. The company cautioned that these obligations could accelerate its need for capital and threaten operations if funding is unavailable.
- Subsequent to quarter-end, the company reported a November common-stock sale for approximately $465,000 under its registered offering. It had also engaged Chardan as sales agent for offerings, with fees and warrants payable under specified arrangements. Equity issuance may dilute existing holders.
- The company reported no material pending legal proceedings and stated that disclosure controls were effective as of October 31, 2014. Management cautioned that controls provide reasonable, not absolute, assurance.
Important facts for investors to verify
- Confirm the issuer identity and correct reporting period given the Pharmacyte/Nuvilex mismatch and the inconsistent index period.
- Review subsequent cash balances, financing activity, and actual cash burn against management’s stated runway, including payments under the cannabinoid license.
- Verify the status, timing, funding, and regulatory requirements for the Phase 2b trial and U.S. studies; the filing reports preparation and development, not completed trials or approvals.
- Assess dilution from outstanding warrants and options, committed compensation shares, and any further sales under the registered offering or sales-agent arrangement.
- Review the completed valuations of the SG Austria interest and diabetes-license contingent obligations, and clarify the timing and terms of the reported $500,000 license payment.